跳至主要内容
临床试验/NCT03506542
NCT03506542已完成2 期

Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C Augmented Phacotrabeculectomy: Clinical Results of a Prospective Randomized Trial

Medical University of Lublin0 个研究点目标入组 53 人开始时间: 2014年6月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
53
主要终点
Mean intraocular pressure (IOP) after the surgery

研究概览

简要总结

  1. Study objective: To assess the efficacy and safety of collagen matrix implant (Ologen®; OLO) in phacotrabeculectomy and to compare with mitomycin C (MMC) augmented phacotrabeculectomy.
  2. Study Design: The study is designed as a prospective randomized trial. Patient who meet the inclusion/exclusion criteria and sign the informed consent form will be included for this study.
  3. Follow-Up: This investigation is including 7 post-operative visits and follow-up within 12 months from the date of surgery. Patients should be seen at postoperative days 1, 7, 30, 90, 180, 270 and 360.

详细描述

  • Prospective randomized comparative study
  • Patients with cataract and:

primary open angle glaucoma (POAG) pseudoexfoliation (PEX) glaucoma (PEXG)

  • Phacotrabeculectomy augmented with OLO or MMC
  • Follow-up - 12 months

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary open angle glaucoma or pseudoexfoliation glaucoma with progression of visual field loss and/or uncontrolled intraocular pressure levels with medication

排除标准

  • Difficulty in reading or speaking Polish
  • Previous ocular surgery
  • Pregnant and breastfeeding women
  • Angle closure glaucoma
  • Secondary glaucoma except pseudoexfoliation glaucoma
  • Ocular diseases with excessive scarring
  • Allergy to collagen or Mitomycin C

研究组 & 干预措施

Ologen (OLO)

Experimental

Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy

干预措施: Ologen (Device)

Ologen (OLO)

Experimental

Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy

干预措施: Phacotrabeculectomy (Procedure)

Mitomycin C (MMC)

Active Comparator

Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)

干预措施: Phacotrabeculectomy (Procedure)

Mitomycin C (MMC)

Active Comparator

Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)

干预措施: Mitomycin C (Drug)

结局指标

主要结局

Mean intraocular pressure (IOP) after the surgery

时间窗: 12 months

Decrease in IOP before and after the surgery

次要结局

  • Mean best corrected visual acuity (BCVA) (LogMAR)(12 months)
  • Evaluation of the filtering bleb in MBGS (Moorfields Bleb Grading System)(12 months)
  • Mean number of antiglaucoma medications(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Aleksandra Wlaz

PhD, ophthalmologist in Department of Diagnostics and Microsurgery of Glaucoma

Medical University of Lublin

相似试验

Phacotrabeculectomy With Collagen Matrix Implant... | 临床试验